Spartalizumab (PDR001) is a humanized IgG4 monoclonal antibody. Spartalizumab binds to PD-1 at picomolar affinity and blocks the interactions with PD-L1 and PD-L2, thereby relieving the inhibition on T cell activity and restoring the immune systems ability to attack tumors. Spartalizumab can be used in the research of undifferentiated thyroid carcinoma (ATC) and neuroendocrine tumors (NENs)[1][2].
Molecular Weight:
(143.14 kDa)
Purity:
99.50
CAS Number:
[1935694-88-4]
Target:
PD-1/PD-L1
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted
